
	Mr. Foletta is a seasoned financial executive with over 30 years of corporate experience.&nbsp; He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc.&nbsp; He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb for approximately $7 billion in August 2012.&nbsp; During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions.&nbsp; As chair of Amylin&#39;s Operating Committee, he had responsibility for business planning, forecasting and assessing performance.&nbsp; He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M.
	
	Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president, Chief Financial Officer and Corporate Secretary.&nbsp; Mark began his career in 1982 as an Audit Manager at Ernst &amp; Young, LLP in San Diego.&nbsp; He holds a B.A. in Business Economics and is a Certified Public Accountant (currently inactive).
